Patent Expiry
Patent/Exclusivity Expiry: IMKELDI
- Company
- Kura Oncology, Inc. (KURA)
- Drug
- IMKELDI
Other upcoming events for KURA
Phase 3 ReadoutPhase 3 Topline: Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination Wit
Patent ExpiryPatent/Exclusivity Expiry: COMETRIQ
Patent ExpiryPatent/Exclusivity Expiry: CABOMETYX
Patent ExpiryPatent/Exclusivity Expiry: VANFLYTA
Patent ExpiryPatent/Exclusivity Expiry: XOSPATA
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.